Smartphone App-assisted PPI (PIPPI)
Status
Conditions
Treatments
Details and patient eligibility
About
Proton pump inhibitors (PPIs) are frequently prescribed for 30 days but taken infinitely. PPIs belong to the most often inappropriate medicines (PIMs). Correct intake of medicines (named adherence) can be supported by digital devices such as smartphone applications. The goal of this interventional study is to test the feasibility of an app-based treatment support provided by community pharmacists in patients prescribed a short-term PPI (30 days). The intervention consists in tracking medication intake, symptom course and well-being over the treatment duration of 30 days with the mednet app on patients' personal smartphones.
Full description
This is an exploratory study in a primary care setting with community pharmacists recruiting patients who are newly prescribed a PPI for a short-term treatment (30 days). There is no control group and no randomization. After informed consent and installing the app on their personal smartphones, patients will answer three questions from the app once daily. The questions address medication intake (yes/no), symptom course (better, worse, identical, no symptoms) and well-being (satisfactory/needs improvement). Worsening of symptoms will trigger an alarm (via email) at the pharmacy. The pharmacist will call the patients and use information from adherence and well-being to consolidate a supporting counseling.
Feasibility and a frequency estimation of the interventions will be the focus of the study in view of a larger implementation study with community pharmacies. Further implementation outcomes will be assessed through interviews and surveys (satisfaction, interprofessional work).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- is ≥18 years old;
- has symptoms that suggest or correspond to gastroesophageal reflux disease (GERD);
- is newly prescribed a short-term PPI treatment;
- accepts to use of the smartphone app mednet during the study period;
- signs the informed consent form;
- understands and speaks (Swiss) German.
Exclusion criteria
- in the opinion of the pharmacist or physician, unlikely to comply with the study schedule or are unsuitable for any other reason.
Trial design
Primary purpose
Allocation
Interventional model
Masking
60 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
Kirstin Messner, MSc; Samuel Allemann, Prof
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal